FDA orders blindness risk warning on weight loss drugs

Impact · against what's priced in

The FDA's blindness risk warning for GLP-1 drugs introduces a new regulatory headwind for Novo Nordisk. This label change is likely to increase prescriber caution, potentially slowing patient acquisition rates for Ozempic and Wegovy.

NVO−0.40

No priced-in read yet

In context

The FDA requirement to add a warning label regarding a rare eye condition that can cause blindness may dampen the growth trajectory of Ozempic and Wegovy by increasing prescriber caution.

Read from the article alone

• healthcare
• pharmaceuticals
• NVO
• drug safety
• fda
• ozempic
• regulatory warning
• wegovy
• weight loss drugs

Search tags